Introduction Serological SARS-CoV-2 assays have an important role in guiding the pandemic response. This research aimed to compare the performance of 2 antinucleocapsid assays. Methods Serum from 49 HCWs was analysed at baseline and 6 months using the Abbott diagnostics SARS-CoV-2 IgG assay and the Roche Diagnostics Elecsys Anti-SARS-CoV-2 total antibody assay. Results At baseline, 14/49 participants (29%) demonstrated antibody reactivity using the Abbott assay. At 6 months, 4/14 participants (29%) continued to demonstrate reactivity. A total of 14/49 (29%) participants had detectable antibodies at baseline using the Roche assay. In total, 13/14 (93%) of participants demonstrated antibody reactivity at 6 months. The Abbott assay showed a statistically significant difference in the signal-to-threshold values of baseline reactive samples when repeated at 6 months (p = 0.001). This was not seen with the Roche assay (p = 0.51). Conclusion In this small study, the Roche Diagnostics Elecsys Anti-SARS-CoV-2 total antibody assay appears superior in performance to the Abbott diagnostics SARS-CoV-2 IgG assay in accurately detecting participants with a history of confirmed COVID-19 disease at 6 months follow-up. This finding should be born in mind in the planning of future seroprevalence studies, especially when considering the use of anti-nucleocapsid assays. Supplementary information The online version contains supplementary material available at 10.1007/s11845-021-02700-5.
【저자키워드】 COVID-19, SARS-CoV-2, antibody, assay, Anti-nucleocapsid, 【초록키워드】 IgG, pandemic, diagnostics, COVID-19 disease, serum, Research, Follow-up, threshold, information, Roche, SARS-CoV-2 IgG, Abbott, HCW, not seen, Planning, supplementary material, signal, statistically significant difference, participant, mind, Roche Diagnostics, Elecsys, Abbott Diagnostics, antibody reactivity, repeated, Result, assays, detectable, analysed, appear, demonstrated, reactivity, baseline, Elecsy, 【제목키워드】 healthcare worker, baseline,